Sir, Most non-typhoidal salmonella infections are self-limiting, but antibiotics can be life-saving for vulnerable patients and invasive disease. Salmonella enterica may exhibit resistance to quinolones and cephalosporins, but carbapenem resistance is rarely reported. 1 Non-duplicate isolates (n¼ 126) of cefotaxime-resistant (MICs .1 mg/L) non-typhoidal S. enterica were screened by disc testing for ertapenem resistance. Briefly, 0.5 McFarland standard cell suspensions in Iso-Sensitest broth were inoculated onto MuellerHinton agar plates and 10 mg ertapenem discs were added. Inhibition zone diameters that measured ≤27 mm after 18 h of incubation at 378C were considered resistant compared with positive controls (not salmonellae) producing NDM-1, KPC, VIM, IMP or OXA-48-like carbapenemases. In addition, 2597 S. enterica isolates from patients with a history of travel to North Africa, the Middle East or the Indian subcontinent (all cephalosporin susceptible) were screened retrospectively. A further 266 S. enterica serovar Typhi, 157 S. enterica serovar Paratyphi A and 10 S. enterica serovar Paratyphi B were screened as part of routine susceptibility testing for high-level temocillin resistance (MICs .128 mg/L; a marker for OXA-48-like enzymes) 2 by breakpoint testing using IsoSensitest agar. The MICs were determined by Etest w (bioMérieux, Basingstoke, UK) and interpreted using BSAC criteria (http://bsac. org.uk/wp-content/uploads/2012/02/Version-12-Apr-2013_final. pdf). Carbapenemase genes (KPC, OXA-48-like, NDM, IMP, VIM, GIM, SIM and SPM) were sought by in-house PCRs with gene variants identified by amplicon sequencing. Non-susceptible isolates were used as plasmid donors in electro-transformation to E. coli Alpha-Select cells (Bioline, London, UK) with the transformants selected on Iso-Sensitest agar containing 128 mg/L ampicillin onto which a 10 mg ertapenem disc had been placed.
One of the 126 cefotaxime-resistant isolates showed reduced ertapenem susceptibility. S. enterica serovar Senftenberg strain H083340277 isolated in 2008 from the faeces of an outpatient with an unknown travel history was resistant to cefotaxime and ceftazidime (MICs .256 mg/L) and to ertapenem (MIC ¼ 2 mg/L), but was susceptible to meropenem and imipenem (MICs ¼ 2 mg/L) ( Table 1) . A bla NDM-1 gene was identified in this isolate. NDM carbapenemases are associated with a diverse range of plasmid backbones; therefore, the total genomic DNA of the NDM plasmid transformant was sequenced to .30× coverage on a HiSeq sequencing system (Illumina, Little Chesterford, UK). The reads were assembled into contigs using VelvetOptimiser (https://github.com/VictorianBioinformatics-Consortium/VelvetOptimiser.git), of which three contigs encoding the NDM plasmid were subtracted from the known E. coli host genome and linked by PCR-based gap closure and Sanger DNA sequencing to determine that bla NDM-1 was located on a 53 133 bp complete plasmid sequence. SNP-calling using Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2) and SAMtools (http://samtools.sourceforge.net) showed 99.7% identity to an IncX3-type bla NDM-1 plasmid from a Raoultella planticola isolated in China (GenBank KF877335), with only 13 SNPs to distinguish them. In both plasmids, bla NDM-1 was flanked upstream by ISAba125 (interrupted by IS5), with the bleomycin resistance gene ble MBL located downstream and with bla SHV-12 as the only other co-resident resistance gene.
Temocillin MICs .128 mg/L were observed for two isolates from 2013: S. enterica serovar Typhimurium definitive phage type 193 strain H132980529 from an inpatient with diarrhoea and a history of travel to Africa and S. enterica serovar Paratyphi B phage type Dundee strain H134000562 from an inpatient with diarrhoea and vomiting reporting no recent travel. Both isolates showed reduced susceptibility to cefotaxime (MICs 2 mg/L) and ceftazidime susceptibility (MICs 0.5 mg/L), indicating that there were no co-resident ESBL or AmpC genes; they showed intermediate susceptibility to ertapenem (MICs 1 mg/L), and susceptibility to meropenem and imipenem (MICs 0.25 -0.5 mg/L) ( Table 1) . bla OXA-48 was identified in both isolates. Previous studies have shown that the international dissemination of bla OXA-48 is largely due to a single plasmid, pOXA-48a. 3 PCR for repA, traU and parA, encoding the replication, transfer and partitioning proteins, respectively, of pOXA-48a, were positive, 3 indicating that bla OXA-48 was located on a pOXA-48a-like IncL/M plasmid in both isolates. The bla OXA-48 plasmid sizes, as determined following alkaline extraction from the transformants, were compatible with the carriage of 62 kb pOXA-48a plasmids.
We report the first carbapenemase-producing S. enterica isolates in the UK, one carrying bla NDM-1 and two carrying bla OXA-48 . In Salmonella, bla NDM-1 was first reported in serovar Senftenberg in 2011 located on an IncL/M plasmid. 4 ,5 bla NDM-1 has also been identified in S. enterica serovars Westhampton and Stanley. 6, 7 The bla NDM-1 S. enterica serovar Senftenberg identified in this study predates the earliest isolate reported by 3 years. bla NDM-1 has previously been reported as being co-located with bla SHV-12 on 50 kb IncX3 plasmids in multiple genera of Enterobacteriaceae, 8 suggesting that these IncX3 plasmids are a successful vehicle in the spread of bla NDM-1 .
bla OXA-48 has previously been identified in S. enterica serovars Kentucky and Saintpaul. 9, 10 The detection of only one bla OXA-48 -positive isolate among patients (n¼ 2597) with a history of travel to areas where bla OXA-48 Enterobacteriaceae are endemic suggests that S. enterica is not a significant reservoir of bla OXA-48 in these countries.
The MICs of meropenem and imipenem for the three isolates reported here lie below the BSAC clinical breakpoints, indicating that reliance on these breakpoints for the detection of carbapenemase producers lacks sensitivity. However, the MICs of ertapenem and meropenem (but not imipenem for the bla OXA-48 -positive isolates) exceeded the recommended EUCAST screening cut-off values for recognizing possible carbapenemase-producing Enterobacteriaceae (http://www.eucast.org/fileadmin/src/media/ PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_ resistance_mechanisms_v1.0_20131211.pdf).
S. enterica has the potential to act as a reservoir for carbapenemase genes within the community and to lead to the transmission of carbapenem resistance via the food chain. An ongoing surveillance of resistance is important so that appropriate control measures can be instigated.
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We have no personal conflicts of interest to declare. However, PHE's AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Achaogen Inc, Allecra Antiinfectives GmbH, Amplex, AstraZeneca UK Ltd, Becton Dickinson Diagnostics, The BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Sir, Resistance of uropathogens to the prescribed antibiotic is linked to significantly worse clinical outcomes; 1,2 hence, surveillance data are important to help guide empirical therapy of urinary tract infection (UTI). However, there are few relevant data on antimicrobial resistance in uropathogenic Escherichia coli in primary care despite UTI being a common reason for consultation. There is a clear tension between the use of broad-spectrum agents to adequately cover resistant E. coli and the risk of developing antibiotic-associated Clostridium difficile and further emergence of resistance. 3 Hence, data to facilitate targeted and appropriate therapy are highly relevant to improving cure rates and minimizing adverse events.
We determined the activity of 15 antimicrobials against 193 consecutive E. coli urinary isolates received from primary care by a large centralized laboratory covering a population of 490 000 in a predominantly urban setting in south-west England. MICs were determined using the CLSI M07-A8 agar dilution method using Mueller -Hinton agar. 4 Tazobactam was tested at a fixed concentration of 4 mg/L and sodium clavulanate was used at a fixed concentration of 2 mg/L. Glucose-6-phosphate was added to the medium for determination of fosfomycin MICs. All antimicrobial powders were sourced from Sigma Life Sciences, Poole, Dorset, UK, with the exception of fosfomycin, which was supplied by Nordic Pharma. E. coli ATCC 25923 and Pseudomonas aeruginosa ATCC 25783 were used as control strains. The MIC range, MIC 50 and MIC 90 of each antimicrobial were determined and the percentages of strains susceptible according to the EUCAST clinical breakpoints 5 were determined where they were available. Isolates were collected between December 2013 and February 2014 and identified by plating on to chromogenic agar (BD GmbH, Heidelberg, Germany).
The MIC 50 , MIC 90 , MIC range and percentage susceptible, intermediate or resistant are shown in Table 1 . For agents widely used or recommended for the therapy of UTI, i.e. amoxicillin, co-amoxiclav and trimethoprim, all agents had levels of susceptibility of ≤65%. Only nitrofurantoin and cefradine had susceptibility rates of .90%. For E. coli, 32.1% were resistant to amoxicillin and trimethoprim, 11.9% were resistant to amoxicillin, trimethoprim and ciprofloxacin and 6.2% were resistant to amoxicillin, co-amoxiclav, trimethoprim and ciprofloxacin. Of the other possible oral agents to treat UTI, co-trimoxazole offered little advantage compared with trimethoprim alone (percentage susceptible: 63.7% versus 58%) while only cefixime and fosfomycin had clinically useful in vitro activity against .90% of strains. There is no published breakpoint for cycloserine against E. coli; however, 63.2% of strains had MICs of ≤32 mg/L and all strains had MICs of ≤128 mg/L. For the agents commonly used to treat community-acquired urosepsis in hospital, only 65.3% of isolates were susceptible to co-amoxiclav while
